ENDRA

ENDRA Life Sciences is an Ann Arbor, Michigan-based medical device company that develops non-invasive diagnostic tools for measuring liver fat and tissue composition using a combination of radiofrequency signals and ultrasound. The publicly traded enterprise focuses on providing cost-effective imaging solutions to healthcare providers treating global health issues, specifically targeting the clinical management of fatty liver conditions. Operating under the ticker NASDAQ: NDRA, the organization completed its initial public offering in 2017 to fund the ongoing medical device development, regulatory approvals, and commercialization of its proprietary Thermo-Acoustic Enhanced UltraSound platform. The company secured its core United States patents between 2012 and 2015, and its executive leadership team features recognizable figures including acting Chief Executive Officer Alexander Tokman, Chief Financial Officer Richard Jacroux, and Head of Regulatory Affairs Ziad Rouag. ENDRA Life Sciences was founded in 2007 by Michael Thornton.